Endometrial hyperplasia history and symptoms
Endometrial hyperplasia Microchapters
Endometrial hyperplasia history and symptoms On the Web
American Roentgen Ray Society Images of Endometrial hyperplasia history and symptoms
Risk calculators and risk factors for Endometrial hyperplasia history and symptoms
Editor-In-Chief: C. Michael Gibson, M.S., M.D.  Swathi Venkatesan, M.B.B.S.
A positive history of irregular menstrual cycles (PCOD) may be present. A detailed drug history may be helpful in the assessment of possible risk factors for endometrial hyperplasia. A history of inappropriate hormone replacement therapy in post menopausal women and history of tamoxifen use in breast cancer patients may be present.
- Bleeding during the menstrual period that is heavier or lasts longer than usual
- Menstrual cycles that are shorter than 21 days (counting from the first day of the menstrual period to the first day of the next menstrual period)
- Any bleeding after menopause
- A detailed drug history may be helpful in the assessment of possible risk factors for endometrial hyperplasia.
- Inappropriate hormone replacement therapy in post menopausal women (with insufficient progesterone component)
- History of tamoxifen use
- Tamoxifen is a non-steroidal anti-estrogen that binds to the estrogen receptor and is used primarily for adjuvant therapy in breast cancer
- Tamoxifen may also act as an estrogen agonist in a low estradiol environment
- Up to 50% of breast cancer patients who are treated with tamoxifen may develop an endometrial lesion within 6-36 months
- Any patient who develops bleeding while on tamoxifen needs evaluation
- A positive history of irregular menstrual cycles (PCOD) may be present.
We observed an association between EH/EC and a history of gestational diabetes specific to younger women. Future studies focusing on the relationships between gestational diabetes, obesity, and EC, including age at diagnosis, are warranted.
- The majority of patients with endometrial hyperplasia present with abnormal uterine bleeding.
- Any postmenopausal bleeding should raise suspicion for malignancy.
- ↑ 1.0 1.1 1.2 Endometrial hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 10, 2016.
- ↑ 2.0 2.1 Emons G, Beckmann MW, Schmidt D, Mallmann P, Uterus commission of the Gynecological Oncology Working Group (AGO) (2015). "New WHO Classification of Endometrial Hyperplasias". Geburtshilfe Frauenheilkd. 75 (2): 135–136. doi:10.1055/s-0034-1396256. PMC 4361167. PMID 25797956.
- ↑ 3.0 3.1 Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, Allison K; et al. (2009). "Incidence of endometrial hyperplasia". Am J Obstet Gynecol. 200 (6): 678.e1–6. doi:10.1016/j.ajog.2009.02.032. PMC 2692753. PMID 19393600.
- ↑ 4.0 4.1 Tamoxifen associated endometrial changes. Radiopedia. http://radiopaedia.org/articles/tamoxifen-associated-endometrial-changes Accessed on March 10, 2016
- ↑ Wartko PD, Beck TL, Reed SD, Mueller BA, Hawes SE (August 2017). "Association of endometrial hyperplasia and cancer with a history of gestational diabetes". Cancer Causes Control. 28 (8): 819–828. doi:10.1007/s10552-017-0908-9. PMID 28577154.